IL162391A0 - Method of treatment - Google Patents

Method of treatment

Info

Publication number
IL162391A0
IL162391A0 IL16239102A IL16239102A IL162391A0 IL 162391 A0 IL162391 A0 IL 162391A0 IL 16239102 A IL16239102 A IL 16239102A IL 16239102 A IL16239102 A IL 16239102A IL 162391 A0 IL162391 A0 IL 162391A0
Authority
IL
Israel
Prior art keywords
treatment
darifenacin
urgency
medicament
manufacture
Prior art date
Application number
IL16239102A
Other languages
English (en)
Original Assignee
Pharmaceutical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9927643&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL162391(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmaceutical Ltd filed Critical Pharmaceutical Ltd
Publication of IL162391A0 publication Critical patent/IL162391A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Chemical Treatment Of Metals (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Processing Of Meat And Fish (AREA)
  • Document Processing Apparatus (AREA)
  • Inorganic Insulating Materials (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
IL16239102A 2001-12-14 2002-03-05 Method of treatment IL162391A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0129962.7A GB0129962D0 (en) 2001-12-14 2001-12-14 Method of treatment
PCT/IB2002/000664 WO2003051354A1 (en) 2001-12-14 2002-03-05 Method of treatment

Publications (1)

Publication Number Publication Date
IL162391A0 true IL162391A0 (en) 2005-11-20

Family

ID=9927643

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16239102A IL162391A0 (en) 2001-12-14 2002-03-05 Method of treatment
IL162391A IL162391A (en) 2001-12-14 2004-06-07 Use of darifenacin in the manufacture of medicaments for reducing urgency in dry overactive bladder patients

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL162391A IL162391A (en) 2001-12-14 2004-06-07 Use of darifenacin in the manufacture of medicaments for reducing urgency in dry overactive bladder patients

Country Status (28)

Country Link
US (3) US20030130338A1 (ko)
EP (1) EP1458376B1 (ko)
JP (3) JP2005516925A (ko)
KR (1) KR100889086B1 (ko)
CN (1) CN100488505C (ko)
AT (1) ATE341323T1 (ko)
AU (1) AU2002236141B2 (ko)
BR (1) BR0214925A (ko)
CA (1) CA2469702C (ko)
CY (1) CY1105814T1 (ko)
CZ (1) CZ301283B6 (ko)
DE (1) DE60215219T2 (ko)
DK (1) DK1458376T3 (ko)
ES (1) ES2276910T3 (ko)
GB (1) GB0129962D0 (ko)
HK (1) HK1073779A1 (ko)
HU (1) HU229908B1 (ko)
IL (2) IL162391A0 (ko)
MX (1) MXPA04005760A (ko)
NO (1) NO20042586L (ko)
NZ (1) NZ533421A (ko)
PL (1) PL206034B1 (ko)
PT (1) PT1458376E (ko)
RU (1) RU2321398C2 (ko)
SI (1) SI1458376T1 (ko)
SK (1) SK287510B6 (ko)
WO (1) WO2003051354A1 (ko)
ZA (1) ZA200404289B (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007109142A2 (en) * 2006-03-17 2007-09-27 Oregon Health & Science University M3 muscarinic receptor antagonists for treating tumors
CN101084891A (zh) * 2007-06-29 2007-12-12 北京本草天源药物研究院 一种用于口服的达非那新或其药用盐的药物制剂
CZ300895B6 (cs) * 2008-01-28 2009-09-02 Zentiva, A. S. Zpusob prípravy Darifenacinu
US9198904B2 (en) * 2009-02-04 2015-12-01 Astellas Pharma Inc. Pharmaceutical composition for oral administration
CN102048706B (zh) * 2011-01-12 2012-02-22 山东创新药物研发有限公司 一种氢溴酸达非那新缓释片及制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8906166D0 (en) * 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations

Also Published As

Publication number Publication date
KR20040066892A (ko) 2004-07-27
PL206034B1 (pl) 2010-06-30
JP2010024244A (ja) 2010-02-04
CA2469702C (en) 2010-07-06
CA2469702A1 (en) 2003-06-26
DE60215219T2 (de) 2007-10-18
DK1458376T3 (da) 2007-02-12
BR0214925A (pt) 2004-12-21
US20030130338A1 (en) 2003-07-10
CN100488505C (zh) 2009-05-20
GB0129962D0 (en) 2002-02-06
ATE341323T1 (de) 2006-10-15
AU2002236141B2 (en) 2007-02-01
CZ301283B6 (cs) 2009-12-30
JP2013199506A (ja) 2013-10-03
NZ533421A (en) 2007-02-23
EP1458376A1 (en) 2004-09-22
WO2003051354A1 (en) 2003-06-26
DE60215219D1 (de) 2006-11-16
PL369426A1 (en) 2005-04-18
KR100889086B1 (ko) 2009-03-16
SI1458376T1 (sl) 2007-06-30
US8748476B2 (en) 2014-06-10
CY1105814T1 (el) 2011-02-02
CN1604777A (zh) 2005-04-06
SK287510B6 (sk) 2010-12-07
JP2005516925A (ja) 2005-06-09
ZA200404289B (en) 2005-09-28
RU2004121780A (ru) 2005-08-10
US20070264333A1 (en) 2007-11-15
IL162391A (en) 2012-04-30
EP1458376B1 (en) 2006-10-04
HU229908B1 (hu) 2014-12-29
US20090162433A1 (en) 2009-06-25
PT1458376E (pt) 2007-01-31
NO20042586L (no) 2004-06-18
HK1073779A1 (en) 2005-10-21
RU2321398C2 (ru) 2008-04-10
SK2502004A3 (en) 2004-10-05
CZ2004719A3 (cs) 2005-01-12
MXPA04005760A (es) 2005-03-31
ES2276910T3 (es) 2007-07-01
AU2002236141A1 (en) 2003-06-30
HUP0402625A2 (hu) 2005-04-28

Similar Documents

Publication Publication Date Title
MY127290A (en) New use of flibanserin
YU37602A (sh) Derivat pirolidinacetamida sam ili u kombinaciji za tretman poremećaja cns
PL1663244T3 (pl) Pochodne pterydyny do leczenia chorób związanych z TNF-alfa
YU71901A (sh) NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA
WO2004043341A3 (en) Treatment for hemorrhagic shock
GB0002336D0 (en) Medicaments
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
HK1073779A1 (en) The use of darifenacin and the salt thereof
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
IL143985A0 (en) New use of melagatran
EP1262197A3 (en) Combination treatment for sleep disorders including sleep apnea
GB0020504D0 (en) Therapeutic method
BG108452A (en) Tablet comprising cetirizine and pseudoephedrine
SE9902597D0 (sv) New use
IL158186A0 (en) Pharmaceutically active compounds and methods of use
HK1047695A1 (en) Use of beta-adrenoceptor antagonists for the manufacture of a medicament for the treatment of disorders of the outer retina
MXPA04001805A (es) Nueva forma de dosificacion oral de liberacion prolongada.
HK1075390A1 (en) Citalopram for the treatment of elevated blood pressure
UA83017C2 (uk) Комбінація рофлуміласту та r,r-формотеролу для лікування захворювань дихальних шляхів
PL367628A1 (en) Use of an alkanoyl l-carnitine for the preparation of a medication to treat anhedonia
NZ514490A (en) Method and means for treating post-polio syndrome
GB0208129D0 (en) Method of treatment
GEP20094628B (en) (s,s)-reboxetine for treating fibromyalgia and other somatoform disorders
AU2002240883A1 (en) System and method for improving the medical treatment of a patient
UA43619A (uk) Бетатирон - пролонгований антигіпертензивний засіб нової генерації